Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient

Rheumatology (United Kingdom)

Volumn 54, Issue 1, 2015, Pages 194-195

  Wang, Yu ^a   Zhou, Wei ^a   Zhang, Zhuoli ^a,b  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; COMPLEMENT COMPONENT C3D; DANAZOL; GLUCOCORTICOID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PREDNISONE; RITUXIMAB; ANTIRHEUMATIC AGENT; BORONIC ACID DERIVATIVE; MONOCLONAL ANTIBODY; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE;

AGED; AUTOIMMUNE HEMOLYTIC ANEMIA; CASE REPORT; COOMBS TEST; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG TREATMENT FAILURE; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LETTER; MOUTH ULCER; POLYARTHRITIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; ANEMIA, HEMOLYTIC; CLASSIFICATION; COMORBIDITY; LUPUS ERYTHEMATOSUS, SYSTEMIC; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; ANEMIA, HEMOLYTIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; BORONIC ACIDS; COMORBIDITY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROTEASOME INHIBITORS; PYRAZINES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84925581698     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu393     Document Type: Letter

References (8)

1. Michel M. Classification and therapeutic approaches in autoimmune hemolytic anemia: an update. Expert Rev Hematol 2011;4:607–18.
2. Barros MM, Blajchman MA, Bordin JO. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. Transfus Med Rev 2010;24:195–210.
3. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
4. Neubert K, Meister S, Moser K et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14:748–55.
5. Carson KR, Beckwith LG, Mehta J. Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood 2010;115:915.
6. Danchaivijitr P, Yared J, Rapoport AP. Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide. Am J Hematol 2011;86:331–2.
7. Mehta N, Saxena A, Niesvizky R. Bortezomib-induced thrombotic thrombocytopaenic purpura. BMJ Case Rep 2012;2012:bcr2012006461.
8. Rovira J, Cid J, Gutiérrez-García G. Fatal immune hemolytic anemia following allogeneic stem cell transplantation: report of 2 cases and review of literature. Transfus Med Rev 2013;27:166–70.